US4343804A - 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds - Google Patents

4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds Download PDF

Info

Publication number
US4343804A
US4343804A US06/127,153 US12715380A US4343804A US 4343804 A US4343804 A US 4343804A US 12715380 A US12715380 A US 12715380A US 4343804 A US4343804 A US 4343804A
Authority
US
United States
Prior art keywords
sub
amino
quinolinecarboxylate
ethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/127,153
Other languages
English (en)
Inventor
Harry R. Munson, Jr.
Reevis S. Alphin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
AH Robins Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AH Robins Co Inc filed Critical AH Robins Co Inc
Priority to US06/127,153 priority Critical patent/US4343804A/en
Priority to IL59628A priority patent/IL59628A/xx
Priority to GR61513A priority patent/GR68006B/el
Priority to FI800910A priority patent/FI77452C/fi
Priority to IE605/80A priority patent/IE49577B1/en
Priority to FR8006516A priority patent/FR2452485B1/fr
Priority to AT0156480A priority patent/AT372373B/de
Priority to MX808722U priority patent/MX6264E/es
Priority to DK128380A priority patent/DK156056C/da
Priority to DE19803011490 priority patent/DE3011490A1/de
Priority to CH234080A priority patent/CH644105A5/fr
Priority to IN345/CAL/80A priority patent/IN151446B/en
Priority to CS207380A priority patent/CS216527B2/cs
Priority to EG80174A priority patent/EG15009A/xx
Priority to NL8001752A priority patent/NL8001752A/nl
Priority to BR8001779A priority patent/BR8001779A/pt
Priority to NO800858A priority patent/NO153927C/no
Priority to NZ193252A priority patent/NZ193252A/en
Priority to PT71008A priority patent/PT71008B/pt
Priority to PL1980222993A priority patent/PL125030B1/pl
Priority to SE8002292A priority patent/SE435837B/sv
Priority to GB8009991A priority patent/GB2047244B/en
Priority to ES489887A priority patent/ES489887A0/es
Priority to PH23804A priority patent/PH16416A/en
Priority to YU844/80A priority patent/YU41702B/xx
Priority to IT67465/80A priority patent/IT1133079B/it
Priority to CA000348417A priority patent/CA1147338A/en
Priority to AR280455A priority patent/AR230268A1/es
Priority to AU56848/80A priority patent/AU528388B2/en
Publication of US4343804A publication Critical patent/US4343804A/en
Application granted granted Critical
Priority to CA000416431A priority patent/CA1161757A/en
Priority to SG336/83A priority patent/SG33683G/en
Priority to HK679/83A priority patent/HK67983A/xx
Priority to JP1250369A priority patent/JPH02117663A/ja
Assigned to A.H. ROBINS COMPANY, INCORPORATED, A DE CORP. reassignment A.H. ROBINS COMPANY, INCORPORATED, A DE CORP. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). 12-14-89 DELAWARE Assignors: A.H. ROBINS COMPANY, INCORPORATED, A CORP. OF VA (INTO)
Assigned to AMERICAN HOME PRODUCTS CORP. reassignment AMERICAN HOME PRODUCTS CORP. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: "A.H. ROBINS COMPANY, INCORPORATED", A DELAWARE CORP.
Anticipated expiration legal-status Critical
Assigned to AMERICAN HOME PRODUCTS CORPORATION reassignment AMERICAN HOME PRODUCTS CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: A.H. ROBINS COMPANY, INCORPORATED A DELAWARE CORPORATION
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to certain 4-amino-3-quinolinecarboxylic acids and esters and novel pharmaceutical use and compositions therefor. More particularly, the invention relates to certain 4-amino-3-quinolinecarboxylic acids and esters which reduce gastric secretion stimulated by secretagogues such as histamine, tetragastrin, and food and as such are useful in preventing or treating peptic ulcers in mammals. Certain of the compounds are novel.
  • the compounds useful in the novel method of inhibiting secretion of hydrochloric acid and treating peptic ulcers in mammals, in the present invention are 4-amino-3-quinolinecarboxylic acids and esters which have the formula: ##STR2## wherein: R 1 is selected from the group consisting of loweralkyl, phenyl, O-loweralkyl, S-loweralkyl, halogen, trifluoromethyl, cyano and dialkylamino,
  • R 2 is selected from the group consisting of loweralkyl, phenyl, phenylloweralkyl or phenyl substituted by 1-3 radicals taken from among loweralkyl, O-loweralkyl, S-loweralkyl, halogen, cyano, hydroxy, carbamoyl, carboxy, acetyl, trifluoromethyl, and nitro,
  • R 3 is selected from the group consisting of hydrogen, loweralkyl, loweralkyldimethylamino, loweralkyl-loweralkoxy, and allyl,
  • n 0, 1 or 2
  • the antisecretory effect of reduced flow of gastric juice and hydrochloric acid in pyloric-ligated rats was demonstrated when the esters of 4-amino-3-quinolinecarboxylic acids of this invention were administered orally, subcutaneously, intraperitoneally, intraduodenally and intravenously. Effective ulceration reduction was also demonstrated in pyloric-ligated rats.
  • the compounds of Formula I as stated hereinabove also were shown to reduce gastric secretion induced, for example, by histamine, tetragastrin and methacholine. Gastric acid output in Heidenhain pouch dogs stimulated with food was also reduced.
  • Another object is to provide a novel method of treating mammals for peptic ulceration which comprises administering to the mammal an effective amount which is a peptic ulcer inhibiting amount of a 4-amino-3-quinolinecarboxylic acid or ester compound of Formula I wherein R 1 , R 2 , R 3 , and n are as defined hereinabove.
  • Another object is to provide novel 4-amino-3-quinolinecarboxylic acids and esters particularly effective for their control of gastric ulcers.
  • phenylloweralkyl radicals are benzyl (phenylmethyl), ⁇ -methylbenzyl, phenylethyl, phenylpropyl, phenylbutyl, and the like.
  • the compounds of the present invention are prepared from appropriate 4-chloro-3-quinolinecarboxylic acid esters as represented by the following equation: ##STR3## wherein R 1 , R 2 , and n are as hereinabove defined, and R 3 is loweralkyl.
  • R 1 is selected from the group consisting of loweralkyl, phenyl, O-loweralkyl, S-loweralkyl, halogen, trifluoromethyl, cyano and dialkylamino,
  • R 2 is selected from the group consisting of loweralkyl, phenyl, phenylloweralkyl or phenyl substituted by 1-3 radicals taken from among loweralkyl, O-loweralkyl, S-loweralkyl, halogen, cyano, carbamoyl, carboxy, acetyl, trifluoromethyl, and nitro,
  • Preparation 1 illustrates the synthesis procedure used to make the 4-chloro compounds of Formula II which are the starting materials used in making compounds of Formula I.
  • the reacting amine may be used as the reaction solvent.
  • Various solvents are used for recrystallizing.
  • To prepare the free base from a salt the salt is dissolved and a base such as sodium hydroxide is added and the free base is extracted into a suitable organic solvent.
  • To prepare additional salts the free base is mixed with an alcoholic solution of an acid, for example, phosphoric acid or sulfuric acid.
  • esters of the invention generally illustrate the preparation of the ester compounds.
  • the esters of Examples 3 to 71 and 74 to 80 were also prepared by reacting the appropriate amine with the appropriate ethyl 4-chloro-3-quinolinecarboxylate selected from Preparations 1 to 15.
  • Examples 81-84 and 89 illustrate the preparation of esters wherein R 3 is loweralkyl, loweralkyldimethylamino, loweralkyl-loweralkoxy or allyl by the re-esterification of esters wherein R 3 is loweralkyl.
  • the solid was filtered and air-dried to give 6.9 g (95%) of crude material.
  • the solid was dissolved in 300 ml of hot isooctane and the solution was charcoaled and filtered. The volume of the filtrate was reduced to 150 ml. Upon cooling, pale yellow needles separated; 6.5 g (89%); m.p. 120°-121° C.
  • Example 81 Following the procedure of Example 81, the compound of Example 3 was re-esterified with 2-methoxyethanol to give the titled compound.
  • Example 3 Following a procedure similar to that given in Example 81, the compound of Example 3 was re-esterified with 2-dimethylaminoethanol substituting sodium ethoxide catalyst and toluene solvent to give the titled compound.
  • Example 3 Following a procedure similar to that given in Example 81, the compound of Example 3 was re-esterified with 3-dimethylamino-1-propanol substituting toluene sovlent to give the title compound.
  • the titled compound was prepared from the compound of Example 83 and fumaric acid.
  • the titled compound was prepared from the compound of Example 84 and ethereal hydrogen chloride.
  • the titled compound was prepared from the compound of Example 3 and ethanesulfonic acid in absolute ethanol.
  • the titled compound was prepared from the compound of Example 3 and 2-hydroxyethylsulfonic acid in absolute ethanol.
  • Example 1 The compound of Example 1 was administered to pyloric-ligated rats having no artificial stimulation of gastric secretion.
  • the doses used were 33 to 134 ⁇ moles/kg; acid output was inhibited by 38-55%.
  • Effective quantities of the foregoing compounds represented by Formula I may be administered to a living animal body for therapeutic purposes relating to the control of acid release due to histamine stimulation and peptic ulcer control or combatting peptic ulcers in mammals according to usual modes of administration for pharmaceuticals in usual forms such as orally in solution, emulsions, suspensions, pills, tablets, troches, lozenges, pellets, capsules and the like in pharmaceutically acceptable carriers; parenterally in the form of sterile solutions or mixtures.
  • the pharmaceutical carrier employed may be, for example, either a solid or liquid.
  • solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, arachis oil, water or any parenterally acceptable liquid.
  • unit dosages will usually contain the active ingredient in an amount to supply 2 to 6 mg/kg to the host.
  • Unit dosages may vary from 100 to 500 mg active agent, preferably for an adult human from 200 to 500 mg.
  • the active ingredient will preferably be administered in equal doses one to four times per day.
  • the daily dosage regimen will vary from about 100 to about 1200 mg, most preferably from about 300 to 900 mg/day. It is only necessary that the active ingredient constitute an effective amount, i.e., such that a suitable effective dosage will be obtained consistent with the dosage form employed.
  • the exact individual dosages as well as daily dosages will, of course, be determined according to standard medical principles under the direction of a physician or veterinarian.
  • the mixture all except the magnesium stearate and one half of the calcium ammonium alginate, is blended and granulated with ethanol and passed through a number eight mesh screen and the mixture dried 16 hours at 140° F.
  • the dried granulated material is then blended thoroughly with the remainder of the calcium ammonium alginate and magnesium stearate and tableted.
US06/127,153 1979-03-26 1980-03-04 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds Expired - Lifetime US4343804A (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
US06/127,153 US4343804A (en) 1979-03-26 1980-03-04 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
IL59628A IL59628A (en) 1979-03-26 1980-03-14 4-amino-3-quinolinecarboxylic acids and salts and esters thereof and pharmaceutical compositions containing them
GR61513A GR68006B (ja) 1979-03-26 1980-03-22
IE605/80A IE49577B1 (en) 1979-03-26 1980-03-24 8-substituted-4-amino-3-quinolinecarboxylic acids and esters-antisecretory,anti-ulcer compounds
FR8006516A FR2452485B1 (fr) 1979-03-26 1980-03-24 Nouveaux acides et esters 4-amino-3-quinoleinecarboxyliques, utiles notamment comme agents antisecretoires et anti-ulcere
AT0156480A AT372373B (de) 1979-03-26 1980-03-24 Verfahren zur herstellung von neuen 4-amino-3chinolincarbonsaeuren, deren estern und salzen
MX808722U MX6264E (es) 1979-03-26 1980-03-24 Procedimiento para la preparacion de acidos y esteres 4-amino-3-quinolincarboxilicos
FI800910A FI77452C (fi) 1979-03-26 1980-03-24 Foerfarande foer framstaellning av farmaceutiskt anvaendbara 4-amino-3-kinolinkarboxylsyraestrar.
PH23804A PH16416A (en) 1979-03-26 1980-03-25 4-amino-3-quinolinecarboxylic acids and esters-antisecretory,anti-ulcer compounds
CH234080A CH644105A5 (fr) 1979-03-26 1980-03-25 Acides et esters 4-amino-3-quinoleinecarboxyliques, utiles notamment comme agent antisecretoires et anti-ulcere.
IN345/CAL/80A IN151446B (ja) 1979-03-26 1980-03-25
CS207380A CS216527B2 (cs) 1980-03-04 1980-03-25 Způsob výroby 4-amino-3-chinolinkarboxylových kyselin a jejich esterů
EG80174A EG15009A (en) 1979-03-26 1980-03-25 Process for preparing 4-amino-3-quinolinecarboxylic acids and esters-antisecretory;anti-ulcer compounds
NL8001752A NL8001752A (nl) 1979-03-26 1980-03-25 4-amino-3-chinolinecarbonzuren en hun esters als antimaagzuur- en antimaagzweerverbinding.
BR8001779A BR8001779A (pt) 1979-03-26 1980-03-25 Processo para inibir a secrecao de acido gastrico, composto particularmente eficaz para controlar secrecao gastrica e composicao farmaceutica para inibir a secrecao de acido gastrico e/ou tratar ulcera peptica em mamiferos
NO800858A NO153927C (no) 1979-03-26 1980-03-25 Analogifremgangsmaate ved fremstilling av terapeutisk aktive 8-substituerte 4-amino-3-kinolinsyrederivater.
NZ193252A NZ193252A (en) 1979-03-26 1980-03-25 4-amino-3-quinoline carboxylic acid derivatives and pharmaceutical compositions
PT71008A PT71008B (en) 1979-03-26 1980-03-25 Process for preparing 4-amino-3-quinolinecarboxylic acids and antisecretory and anti-ulcer esters thereof of compositions containing said compounds and its use for inhibitingsecretion of hydrochloric acid and/or tretaing peptic ulcers
DK128380A DK156056C (da) 1979-03-26 1980-03-25 Analogifremgangsmaade til fremstilling af 4-amino-3-quinolin-carboxylsyrederivater
SE8002292A SE435837B (sv) 1979-03-26 1980-03-25 4-amino-3-kinolinkarboxylsyror och estrar derav med antisekretorisk och anti-ulceros aktivitet
GB8009991A GB2047244B (en) 1979-03-26 1980-03-25 4-amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
ES489887A ES489887A0 (es) 1979-03-26 1980-03-25 Un procedimiento para preparar derivados del acido 4-amino-3-quimoleincarboxilico.
DE19803011490 DE3011490A1 (de) 1979-03-26 1980-03-25 4-amino-3-chinolincarbonsaeure und derivate davon, verfahren zur herstellung dieser verbindungen und ihreverwendung
PL1980222993A PL125030B1 (en) 1979-03-26 1980-03-25 Method of manufacture of novel derivatives of 4-aminoquinoline-3-carboxylic acid
YU844/80A YU41702B (en) 1979-03-26 1980-03-26 Process for obtaining 4-amino-3-quinoline carboxylate
IT67465/80A IT1133079B (it) 1979-03-26 1980-03-26 Acidi 4 ammino & chinolincarbossilici e loro esteri particolarmente utili come antisecreitivi ed antiulcera
CA000348417A CA1147338A (en) 1979-03-26 1980-03-26 4-amino-3-quinolinecarboxylic acids and esters-antisecretory, anti-ulcer compounds
AR280455A AR230268A1 (es) 1979-03-26 1980-03-26 Procedimiento para la preparacion de acidos y esteres 4-amino-3-quinolincarboxilicos
AU56848/80A AU528388B2 (en) 1979-03-26 1980-03-26 4-amino-3-quinolinecarboxylic acids and esters
CA000416431A CA1161757A (en) 1979-03-26 1982-11-25 4-amino-3-quinolinecarboxylic acids and esters- antisecretory, anti-ulcer compounds
SG336/83A SG33683G (en) 1979-03-26 1983-06-13 8-substituted-4-amino-3-quinoline-carboxylic acids and esters-antisecretory,anti-ulcer compounds
HK679/83A HK67983A (en) 1979-03-26 1983-12-15 8-substituted-4-amino-3-quinaline-carboxylic acids and esters-antisecretary,anti-ulcer compounds
JP1250369A JPH02117663A (ja) 1979-03-26 1989-09-26 ４―アミノ―３―キノリンカルボン酸類およびそのエステル類

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2398179A 1979-03-26 1979-03-26
US06/127,153 US4343804A (en) 1979-03-26 1980-03-04 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US2398179A Continuation-In-Part 1979-03-26 1979-03-26

Publications (1)

Publication Number Publication Date
US4343804A true US4343804A (en) 1982-08-10

Family

ID=26697875

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/127,153 Expired - Lifetime US4343804A (en) 1979-03-26 1980-03-04 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds

Country Status (31)

Country Link
US (1) US4343804A (ja)
JP (1) JPH02117663A (ja)
AR (1) AR230268A1 (ja)
AT (1) AT372373B (ja)
AU (1) AU528388B2 (ja)
BR (1) BR8001779A (ja)
CA (1) CA1147338A (ja)
CH (1) CH644105A5 (ja)
DE (1) DE3011490A1 (ja)
DK (1) DK156056C (ja)
EG (1) EG15009A (ja)
ES (1) ES489887A0 (ja)
FI (1) FI77452C (ja)
FR (1) FR2452485B1 (ja)
GB (1) GB2047244B (ja)
GR (1) GR68006B (ja)
HK (1) HK67983A (ja)
IE (1) IE49577B1 (ja)
IL (1) IL59628A (ja)
IN (1) IN151446B (ja)
IT (1) IT1133079B (ja)
MX (1) MX6264E (ja)
NL (1) NL8001752A (ja)
NO (1) NO153927C (ja)
NZ (1) NZ193252A (ja)
PH (1) PH16416A (ja)
PL (1) PL125030B1 (ja)
PT (1) PT71008B (ja)
SE (1) SE435837B (ja)
SG (1) SG33683G (ja)
YU (1) YU41702B (ja)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806550A (en) * 1986-09-05 1989-02-21 Smithkline & French Laboratories Limited 4-Amino-3-carbonyl substituted quinolines as inhibitors of gastric acid secretion
US5082848A (en) * 1988-02-25 1992-01-21 Smith Kline & French Laboratories, Ltd. Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibitors
US5082841A (en) * 1989-08-10 1992-01-21 Smithkline Beecham Intercredit B.V. 3-carbonyl-4-amino-8-substituted quinoline compounds useful in inhibiting gastric acid secretions.
US5089498A (en) * 1988-02-25 1992-02-18 Smithkline Beckman Intercredit B.V. Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibitors
US5089504A (en) * 1988-02-25 1992-02-18 Smithkline Beckman Intercredit B.V. Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibitors
US5102892A (en) * 1989-03-17 1992-04-07 Basf Aktiengesellschaft 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
US5143920A (en) * 1988-02-25 1992-09-01 Smithkline Beckman Intercredit B.V. Substituted 4-aminoquinoline derivatives as gastric secretion inhibitors
US5362743A (en) * 1993-03-09 1994-11-08 Pfizer Inc. Aminoquinoline derivatives
US5432182A (en) * 1989-02-23 1995-07-11 Smithkline Beecham Intercredit B.V. Compounds substituted quinoline derivatives
WO1995004720A3 (en) * 1993-08-10 1995-08-03 James Black Foundation Limited Gastrin and cck receptor ligands
US5556863A (en) * 1993-06-11 1996-09-17 Astra Aktiebolag Compound for gastric acid secretion inhibition
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US5889021A (en) * 1993-06-11 1999-03-30 Astra Aktiebolag Active Compounds
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US5952504A (en) * 1995-07-12 1999-09-14 Yungjin Pharmaceutical Company, Ltd. 4-amino-3-acylnaphthyridine derivatives
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
WO2001047891A1 (fr) * 1999-12-28 2001-07-05 Eisai Co., Ltd. Composes heterocylciques contenant des groupes de sulfamide
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
WO2002020489A2 (en) * 2000-09-06 2002-03-14 Bristol-Myers Squibb Company QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
WO2005007658A2 (en) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
US20060269600A1 (en) * 2002-02-20 2006-11-30 Altana Pharma Ag Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
EP1950201A1 (en) 1998-09-29 2008-07-30 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US20080193544A1 (en) * 2005-03-16 2008-08-14 Nycomed Gmbh Taste Masked Dosage Form Containing Roflumilast
US20120071505A1 (en) * 2009-08-17 2012-03-22 High Point Pharmaceuticals, Llc Substituted pyridine derivatives, pharmaceutical compositions, and methods of use to treat oxidative stress
US8536206B2 (en) 2003-03-08 2013-09-17 Takeda Gmbh Process for the preparation of roflumilast
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2018087036A1 (en) * 2016-11-11 2018-05-17 Bayer Animal Health Gmbh New anthelmintic quinoline-3-carboxamide derivatives
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US20210177827A1 (en) * 2017-10-25 2021-06-17 Children`S Medical Center Corporation Papd5 inhibitors and methods of use thereof
RU2772283C2 (ru) * 2016-11-11 2022-05-18 Байер Энимэл Хельс ГмбХ Новые антигельминтные хинолин-3-карбоксамидные производные
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11572357B2 (en) 2018-05-09 2023-02-07 Bayer Animal Health Gmbh Quinoline derivatives
US11674163B2 (en) 2010-01-27 2023-06-13 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610981D0 (en) * 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
GB8804447D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8804448D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
DE3917233A1 (de) * 1989-05-26 1990-11-29 Basf Ag 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470186A (en) * 1967-06-02 1969-09-30 American Cyanamid Co Substituted 4-anilino-3-quinolinecarboxylic acids and esters

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4838712A (ja) * 1971-09-18 1973-06-07

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470186A (en) * 1967-06-02 1969-09-30 American Cyanamid Co Substituted 4-anilino-3-quinolinecarboxylic acids and esters

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Hanifin et al., J. Med. Chem., 1969, 12(6) 1096-7.
J. Med. Pharm. Chem., 5 546-58 (1962).
Kermack et al., J. Chem. Soc., 1951, 1389-92.
Sen et al., Chem. Abstr., vol. 52, 13732, (1958).

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806549A (en) * 1986-09-05 1989-02-21 Smith Kline & French Laboratories Limited 4-amino-3-carbonyl substituted quinolines
US4806550A (en) * 1986-09-05 1989-02-21 Smithkline & French Laboratories Limited 4-Amino-3-carbonyl substituted quinolines as inhibitors of gastric acid secretion
EP0259174B1 (en) * 1986-09-05 1992-03-18 Smith Kline & French Laboratories Limited Derivatives of 4-aminoquinoline and their use as medicaments
US5082848A (en) * 1988-02-25 1992-01-21 Smith Kline & French Laboratories, Ltd. Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibitors
US5089498A (en) * 1988-02-25 1992-02-18 Smithkline Beckman Intercredit B.V. Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibitors
US5089504A (en) * 1988-02-25 1992-02-18 Smithkline Beckman Intercredit B.V. Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibitors
US5143920A (en) * 1988-02-25 1992-09-01 Smithkline Beckman Intercredit B.V. Substituted 4-aminoquinoline derivatives as gastric secretion inhibitors
US5432182A (en) * 1989-02-23 1995-07-11 Smithkline Beecham Intercredit B.V. Compounds substituted quinoline derivatives
US5102892A (en) * 1989-03-17 1992-04-07 Basf Aktiengesellschaft 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
US5082841A (en) * 1989-08-10 1992-01-21 Smithkline Beecham Intercredit B.V. 3-carbonyl-4-amino-8-substituted quinoline compounds useful in inhibiting gastric acid secretions.
US5362743A (en) * 1993-03-09 1994-11-08 Pfizer Inc. Aminoquinoline derivatives
US5889021A (en) * 1993-06-11 1999-03-30 Astra Aktiebolag Active Compounds
US5556863A (en) * 1993-06-11 1996-09-17 Astra Aktiebolag Compound for gastric acid secretion inhibition
AU682051B2 (en) * 1993-08-10 1997-09-18 James Black Foundation Limited Gastrin and CCK receptor ligands
WO1995004720A3 (en) * 1993-08-10 1995-08-03 James Black Foundation Limited Gastrin and cck receptor ligands
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US5952504A (en) * 1995-07-12 1999-09-14 Yungjin Pharmaceutical Company, Ltd. 4-amino-3-acylnaphthyridine derivatives
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
EP2253620A1 (en) 1998-09-29 2010-11-24 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
EP2896612A1 (en) 1998-09-29 2015-07-22 Wyeth Holdings LLC Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
EP1950201A1 (en) 1998-09-29 2008-07-30 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
WO2001047891A1 (fr) * 1999-12-28 2001-07-05 Eisai Co., Ltd. Composes heterocylciques contenant des groupes de sulfamide
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6689772B1 (en) 2000-03-28 2004-02-10 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US20040176602A1 (en) * 2000-03-28 2004-09-09 Wyeth 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
WO2002020489A2 (en) * 2000-09-06 2002-03-14 Bristol-Myers Squibb Company QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE
US20070155788A1 (en) * 2000-09-06 2007-07-05 Bristol-Myers Squibb Company Quinoline Inhibitors of cGMP Phosphodiesterase
US6835737B2 (en) 2000-09-06 2004-12-28 Bristol-Myers Squibb Company Quinoline inhibitors of cGMP phosphodiesterase
US20030225128A1 (en) * 2000-09-06 2003-12-04 Yingzhi Bi Quinoline inhibitors of cGMP phosphodiesterase
US20050113358A1 (en) * 2000-09-06 2005-05-26 Yingzhi Bi Quinoline inhibitors of cGMP phosphodiesterase
WO2002020489A3 (en) * 2000-09-06 2002-06-06 Bristol Myers Squibb Co QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7384958B2 (en) 2000-09-06 2008-06-10 Bristol-Myers Squibb Company Quinoline inhibitors of cGMP phosphodiesterase
US7378430B2 (en) 2000-09-06 2008-05-27 Bristol-Myers Squibb Company Quinoline inhibitors of cGMP phosphodiesterase
US7173042B2 (en) 2000-09-06 2007-02-06 Bristol-Myers Squibb Company Quinoline inhibitors of cGMP phosphodiesterase
US20070155775A1 (en) * 2000-09-06 2007-07-05 Bristol-Myers Squibb Company Quinoline Inhibitors of cGMP Phosphodiesterase
US20070117843A1 (en) * 2000-09-06 2007-05-24 Bristol-Myers Squibb Company Quinoline inhibitors of cGMP phosphodiesterase
US20110060016A1 (en) * 2002-02-20 2011-03-10 Nycomed Gmbh Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US20060269600A1 (en) * 2002-02-20 2006-11-30 Altana Pharma Ag Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8536206B2 (en) 2003-03-08 2013-09-17 Takeda Gmbh Process for the preparation of roflumilast
US8618142B2 (en) 2003-03-10 2013-12-31 Takeda Gmbh Process for the preparation of roflumilast
US8604064B2 (en) 2003-03-10 2013-12-10 Takeda Gmbh Process for the preparation of roflumilast
EP2287166A3 (en) * 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060142262A1 (en) * 2003-07-14 2006-06-29 Jones Robert M Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EA010023B1 (ru) * 2003-07-14 2008-06-30 Арена Фармасьютикалз, Инк. Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма
US20070082874A1 (en) * 2003-07-14 2007-04-12 Arena Pharmaceuticlas, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20100093761A1 (en) * 2003-07-14 2010-04-15 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005007658A2 (en) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7625906B2 (en) 2003-07-14 2009-12-01 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20050059650A1 (en) * 2003-07-14 2005-03-17 Jones Robert M. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20070072844A1 (en) * 2003-07-14 2007-03-29 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005007658A3 (en) * 2003-07-14 2005-06-16 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
US20080193544A1 (en) * 2005-03-16 2008-08-14 Nycomed Gmbh Taste Masked Dosage Form Containing Roflumilast
US20120071505A1 (en) * 2009-08-17 2012-03-22 High Point Pharmaceuticals, Llc Substituted pyridine derivatives, pharmaceutical compositions, and methods of use to treat oxidative stress
US11674163B2 (en) 2010-01-27 2023-06-13 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US11896578B2 (en) 2015-01-06 2024-02-13 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
WO2018087036A1 (en) * 2016-11-11 2018-05-17 Bayer Animal Health Gmbh New anthelmintic quinoline-3-carboxamide derivatives
AU2017357503B2 (en) * 2016-11-11 2022-02-17 Bayer Animal Health Gmbh New anthelmintic quinoline-3-carboxamide derivatives
RU2772283C2 (ru) * 2016-11-11 2022-05-18 Байер Энимэл Хельс ГмбХ Новые антигельминтные хинолин-3-карбоксамидные производные
CN109890793B (zh) * 2016-11-11 2022-11-18 拜耳动物保健有限责任公司 新的抗蠕虫药喹啉-3-甲酰胺衍生物
US11505545B2 (en) 2016-11-11 2022-11-22 Bayer Animal Health Gmbh Anthelmintic quinoline-3-carboxamide derivatives
US10889573B2 (en) 2016-11-11 2021-01-12 Bayer Animal Health Gmbh Anthelmintic quinoline-3-carboxamide derivatives
TWI821165B (zh) * 2016-11-11 2023-11-11 德商拜耳動物保健有限公司 新穎喹啉衍生物
JP2019535706A (ja) * 2016-11-11 2019-12-12 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 新規な駆虫性キノリン−３−カルボキサミド誘導体
CN109890793A (zh) * 2016-11-11 2019-06-14 拜耳动物保健有限责任公司 新的抗蠕虫药喹啉-3-甲酰胺衍生物
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US20210177827A1 (en) * 2017-10-25 2021-06-17 Children`S Medical Center Corporation Papd5 inhibitors and methods of use thereof
US11572357B2 (en) 2018-05-09 2023-02-07 Bayer Animal Health Gmbh Quinoline derivatives

Also Published As

Publication number Publication date
EG15009A (en) 1985-03-31
NZ193252A (en) 1984-04-27
YU84480A (en) 1983-10-31
HK67983A (en) 1983-12-23
IT8067465A0 (it) 1980-03-26
CH644105A5 (fr) 1984-07-13
PH16416A (en) 1983-09-29
DE3011490C2 (ja) 1988-12-22
IT1133079B (it) 1986-07-09
IN151446B (ja) 1983-04-23
FR2452485A1 (fr) 1980-10-24
DK156056C (da) 1989-11-06
ATA156480A (de) 1983-02-15
IL59628A (en) 1983-06-15
AU5684880A (en) 1980-10-02
NO153927C (no) 1986-06-18
SG33683G (en) 1985-03-29
NL8001752A (nl) 1980-09-30
FI77452B (fi) 1988-11-30
NO153927B (no) 1986-03-10
PT71008B (en) 1981-06-25
AU528388B2 (en) 1983-04-28
BR8001779A (pt) 1980-11-18
GB2047244A (en) 1980-11-26
AT372373B (de) 1983-09-26
ES8103048A1 (es) 1981-02-16
FI77452C (fi) 1989-03-10
PL222993A1 (ja) 1981-01-30
PL125030B1 (en) 1983-03-31
MX6264E (es) 1985-02-19
DK156056B (da) 1989-06-19
YU41702B (en) 1987-12-31
DE3011490A1 (de) 1981-03-12
SE8002292L (sv) 1980-09-27
NO800858L (no) 1980-09-29
PT71008A (en) 1980-04-01
GB2047244B (en) 1983-02-23
FI800910A (fi) 1980-09-27
IE800605L (en) 1980-09-26
CA1147338A (en) 1983-05-31
ES489887A0 (es) 1981-02-16
SE435837B (sv) 1984-10-22
AR230268A1 (es) 1984-03-01
IL59628A0 (en) 1980-06-30
JPH02117663A (ja) 1990-05-02
GR68006B (ja) 1981-10-26
DK128380A (da) 1980-09-27
IE49577B1 (en) 1985-10-30
FR2452485B1 (fr) 1986-09-12

Similar Documents

Publication Publication Date Title
US4343804A (en) 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
EP0322133B1 (en) Quinazoline derivatives
US5064833A (en) Substituted quinazoline derivatives for use in gastrointestinal diseases
US3669968A (en) Trialkoxy quinazolines
US4738971A (en) N-aryl-1,2-dihydro-4-substituted-1-alkyl-2-oxo-quinoline-3-carboxamides
DE69530989T2 (de) Neue pyrimidinderivate und verfahren zu ihrer herstellung
US3702849A (en) 4-(isoquinolin-1-yl) piperazine-1-carboxylic acid esters
AU648394B2 (en) 4-aryl-thiazole or imidazole derivatives
DE2740588A1 (de) Imidazo- eckige klammer auf 1,2-a eckige klammer zu -chinolin-2-carbon- saeuren und deren derivate sowie pharmazeutische zubereitungen, die diese verbindungen enthalten
CA1168232A (en) Isoquinoline derivatives, a process for their preparation, pharmaceutical formulations containing them and their use
GB1596652A (en) Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives
DE3216843C2 (de) 3-Thiomethyl-pyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
PL128505B1 (en) Process for preparing novel 2-/4-(diphenylmethylene)-1-piperidinyl/-acetic acids
JPS5946220B2 (ja) 複素環化合物の製法
US3745216A (en) Compositions and methods for producing hypotensive activity with imidazo and pyrimido(2,1-b)quinazoline compounds
KR840000768B1 (ko) 4-아미노-3-퀴놀린카복실산 및 에스테르의 제조방법
CA1161757A (en) 4-amino-3-quinolinecarboxylic acids and esters- antisecretory, anti-ulcer compounds
CA1086758A (en) Amino-alkyl-isothioureas and processes for their preparation
CA2029222A1 (en) Pyridine derivatives, pharmaceutical compositions containing them and process for preparing same
US3654296A (en) 2-chlorobenzothiazolecarboxamides
HU196998B (en) Process for producing basically substituted pyridine derivatives and pharmaceuticals comprising same
US4333951A (en) 2-Amino-6-biphenylacetic acids
EP0089426B1 (en) 2-amino-6-biphenylacetic acids
AU610328B2 (en) 2,4- diaminoquinazoline derivatives
CS216527B2 (cs) Způsob výroby 4-amino-3-chinolinkarboxylových kyselin a jejich esterů

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: A.H. ROBINS COMPANY, INCORPORATED, A DE CORP.

Free format text: CHANGE OF NAME;ASSIGNOR:A.H. ROBINS COMPANY, INCORPORATED, A CORP. OF VA (INTO);REEL/FRAME:005587/0178

Effective date: 19891213

AS Assignment

Owner name: AMERICAN HOME PRODUCTS CORP., NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:"A.H. ROBINS COMPANY, INCORPORATED", A DELAWARE CORP.;REEL/FRAME:009605/0374

Effective date: 19980803

AS Assignment

Owner name: AMERICAN HOME PRODUCTS CORPORATION, NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:A.H. ROBINS COMPANY, INCORPORATED A DELAWARE CORPORATION;REEL/FRAME:010557/0222

Effective date: 19980803